TRIM29

Across TCGA pan-cancer cohorts, TRIM29 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRIM29 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRIM29 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRIM29 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where TRIM29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	1.000	0.277	.013	27	view →
PDAC	DFS	Tertile	All	0.317	0.450	.031	8	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.807	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRIM29–HNSC (OS)

Open the HNSC breakdown →